Mirae Asset Healthcare Fund Direct Growth

Fund Overview

Fund Size

₹2,441 Cr

Expense Ratio

0.52%

ISIN

INF769K01ED6

Minimum SIP

₹1,000

Exit Load

1.00%

Inception Date

02 Jun 2018

About this fund

Mirae Asset Healthcare Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by Mirae Asset India Mutual Fund. This fund has been in existence for 6 years, 9 months and 26 days, having been launched on 02-Jun-18.
As of 27-Mar-25, it has a Net Asset Value (NAV) of ₹40.39, Assets Under Management (AUM) of 2441.13 Crores, and an expense ratio of 0.52%.

Mirae Asset Healthcare Fund Direct Growth has given a CAGR return of 22.72% since inception.
The fund's asset allocation comprises around 99.60% in equities, 0.00% in debts, and 0.39% in cash & cash equivalents.
You can start investing in Mirae Asset Healthcare Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+19.94%

+17.95% (Cat Avg.)

3 Years

+19.48%

+18.51% (Cat Avg.)

5 Years

+30.89%

+28.12% (Cat Avg.)

Since Inception

+22.72%

— (Cat Avg.)

Portfolio Summaryas of 28th February 2025

Equity	₹2,431.48 Cr	99.60%
Others	₹9.66 Cr	0.40%

Top Holdings

All Holdings

Equity

Debt & Others

Name	Type	Amount	Holdings
Sun Pharmaceuticals Industries Ltd	Equity	₹288.92 Cr	11.84%
Cipla Ltd	Equity	₹185.52 Cr	7.60%
Aurobindo Pharma Ltd	Equity	₹173.14 Cr	7.09%
Divi's Laboratories Ltd	Equity	₹159.36 Cr	6.53%
Lupin Ltd	Equity	₹155.26 Cr	6.36%
Apollo Hospitals Enterprise Ltd	Equity	₹133.79 Cr	5.48%
Glenmark Pharmaceuticals Ltd	Equity	₹129.63 Cr	5.31%
Suven Pharmaceuticals Ltd	Equity	₹108.17 Cr	4.43%
Dr Reddy's Laboratories Ltd	Equity	₹108.02 Cr	4.42%
Krishna Institute of Medical Sciences Ltd	Equity	₹87.2 Cr	3.57%
Gland Pharma Ltd	Equity	₹83.65 Cr	3.43%
Torrent Pharmaceuticals Ltd	Equity	₹73.97 Cr	3.03%
J.B. Chemicals & Pharmaceuticals Ltd	Equity	₹73.81 Cr	3.02%
Syngene International Ltd	Equity	₹72.1 Cr	2.95%
Mankind Pharma Ltd	Equity	₹70.38 Cr	2.88%
Alkem Laboratories Ltd	Equity	₹67.86 Cr	2.78%
Sai Life Sciences Ltd	Equity	₹61.05 Cr	2.50%
Wockhardt Ltd	Equity	₹59.69 Cr	2.45%
Fortis Healthcare Ltd	Equity	₹53.8 Cr	2.20%
Ipca Laboratories Ltd	Equity	₹50.17 Cr	2.06%
Aster DM Healthcare Ltd Ordinary Shares	Equity	₹45.97 Cr	1.88%
OneSource Specialty Pharma Ltd	Equity	₹45.76 Cr	1.87%
Biocon Ltd	Equity	₹29.15 Cr	1.19%
Zydus Lifesciences Ltd	Equity	₹23.38 Cr	0.96%
Sagility India Ltd	Equity	₹22.54 Cr	0.92%
Alembic Pharmaceuticals Ltd	Equity	₹20.64 Cr	0.85%
Neogen Chemicals Ltd	Equity	₹17.19 Cr	0.70%
Laxmi Dental Ltd	Equity	₹13.81 Cr	0.57%
SRF Ltd	Equity	₹12.32 Cr	0.50%
Treps	Cash - Repurchase Agreement	₹8.57 Cr	0.35%
Deepak Nitrite Ltd	Equity	₹3.71 Cr	0.15%
Suraksha Diagnostic Ltd	Equity	₹1.49 Cr	0.06%
Net Receivables / (Payables)	Cash	₹0.87 Cr	0.04%
Mirae Asset Liquid Dir Gr	Mutual Fund - Open End	₹0.22 Cr	0.01%

Allocation By Market Cap (Equity)

Other Allocation

Equity Sector

Debt & Others

Sector	Amount	Holdings
Healthcare	₹2,398.26 Cr	98.24%
Basic Materials	₹20.9 Cr	0.86%
Industrials	₹12.32 Cr	0.50%

Risk & Performance Ratios

Fund Managers

Vrijesh Kasera

Since July 2018

Additional Scheme Detailsas of 28th February 2025

ISIN

INF769K01ED6

Expense Ratio

0.52%

Exit Load

1.00%

Fund Size

₹2,441 Cr

Age

6 years 9 months

Lumpsum Minimum

₹5,000

Fund Status

Open Ended Investment Company

Benchmark

BSE Healthcare TR INR

Investment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Capital Gains Taxation:

Dividend Taxation:

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Motilal Oswal S&P BSE Healthcare ETF Very High Risk	0.2%	-	₹25.63 Cr	20.0%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk	1.1%	1.0%	₹754.75 Cr	13.4%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹754.75 Cr	11.9%
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk	0.2%	-	₹37.95 Cr	15.9%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹200.83 Cr	19.0%
ITI Pharma and Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹200.83 Cr	16.8%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹2441.13 Cr	19.9%
Mirae Asset Healthcare Fund Regular Growth Very High Risk	2.0%	1.0%	₹2441.13 Cr	18.2%
Nippon India Nifty Pharma ETF Very High Risk	0.2%	-	₹809.18 Cr	13.8%
Axis NIFTY Healthcare ETF Very High Risk	0.3%	-	₹17.44 Cr	15.8%

About the AMC

Mirae Asset India Mutual Fund

022-6780 0300

https://www.miraeassetmf.co.in/

Total AUM

₹1,90,161 Cr

Address

Unit No. 606, 6th Floor, Mumbai, 400 098

Other Funds by Mirae Asset India Mutual Fund

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Mirae Asset Multi Asset Allocation Fund Direct Growth High Risk	0.4%	1.0%	₹1799.77 Cr	14.0%
Mirae Asset Great Consumer Fund Direct Growth Very High Risk	0.5%	1.0%	₹3642.65 Cr	8.2%
Mirae Asset Cash Management Direct Growth Low to Moderate Risk	0.1%	0.0%	₹12730.95 Cr	7.4%
Mirae Asset Emerging Bluechip Direct Growth Very High Risk	0.6%	1.0%	₹33677.94 Cr	7.4%
Mirae Asset Large Cap Fund Direct Growth Very High Risk	0.6%	1.0%	₹35532.55 Cr	10.8%
Mirae Asset Savings Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹1199.97 Cr	8.1%
Mirae Asset Money Market Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹2474.19 Cr	7.9%
Mirae Asset Focused Fund Direct Growth Very High Risk	0.6%	1.0%	₹7104.55 Cr	9.5%
Mirae Asset Dynamic Bond Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹118.15 Cr	8.1%
Mirae Asset NYSE FANG+ ETF Fund of Fund Direct Growth Very High Risk	0.7%	0.0%	₹1869.44 Cr	39.7%
Mirae Asset Hybrid Equity Fund Direct Growth Very High Risk	0.4%	1.0%	₹8170.45 Cr	11.0%
Mirae Asset Equity Allocator Fund of Fund Direct Growth Very High Risk	0.2%	0.0%	₹804.67 Cr	7.0%
Mirae Asset Nifty 100 ESG Sector Leaders Fund of Fund Direct Growth Very High Risk	0.5%	0.0%	₹89.89 Cr	7.7%
Mirae Asset S&P 500 Top 50 ETF Fund of Fund Direct Growth Very High Risk	0.7%	0.0%	₹668.66 Cr	29.7%
Mirae Asset Nifty SDL Jun 2027 Index Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹766.69 Cr	8.5%
Mirae Asset Ultra Short Duration Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹1588.44 Cr	7.9%
Mirae Asset Flexi Cap Fund Direct Growth Very High Risk	0.5%	1.0%	₹2324.26 Cr	9.9%
Mirae Asset Banking and Financial Services Fund Direct Growth Very High Risk	0.6%	1.0%	₹1681.43 Cr	17.0%
Mirae Asset Multicap Fund Direct Growth Very High Risk	0.5%	1.0%	₹3064.44 Cr	9.8%
Mirae Asset Nifty India Manufacturing ETF Fund of Fund Direct Growth Very High Risk	0.6%	0.0%	₹96.97 Cr	9.1%
Mirae Asset Tax Saver Fund Direct Growth Very High Risk	0.6%	0.0%	₹22411.17 Cr	10.7%
Mirae Asset Nifty SDL Jun 2028 Index Fund Direct Growth Moderate Risk	0.1%	0.0%	₹71.26 Cr	8.8%
Mirae Asset Corporate Bond Fund Direct Growth Moderate Risk	0.2%	0.0%	₹41.19 Cr	8.6%
Mirae Asset Hang Seng TECH ETF Fund of Fund Direct Growth Very High Risk	0.7%	0.0%	₹102.93 Cr	95.2%
Mirae Asset Equity Savings Fund Direct Growth Moderately High risk	0.3%	1.0%	₹1312.96 Cr	10.4%
Mirae Asset Banking and PSU Debt Fund Direct Growth Low to Moderate Risk	0.3%	0.0%	₹47.92 Cr	8.4%
Mirae Asset Global X Artificial Intelligence & Technology ETF Fund of Fund Direct Growth Very High Risk	0.9%	1.0%	₹327.87 Cr	14.9%
Mirae Asset Global Electric & Autonomous Vehicles ETFs Fund of Fund Direct Growth Very High Risk	2.0%	1.0%	₹53.67 Cr	-0.5%
Mirae Asset Overnight Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹1049.26 Cr	6.7%
Mirae Asset Short Term Fund Direct Growth Low to Moderate Risk	0.3%	0.0%	₹341.97 Cr	8.9%
Mirae Asset CRISIL IBX Gilt Index - April 2033 Index Fund Direct Growth Moderate Risk	0.2%	0.0%	₹240.52 Cr	10.1%
Mirae Asset Nifty AAA PSU Bond Plus SDL Apr 2026 50:50 Index Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹94.16 Cr	7.8%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹2441.13 Cr	19.9%
Mirae Asset Arbitrage Fund Direct Growth Low Risk	0.1%	0.0%	₹2969.67 Cr	7.9%
Mirae Asset Midcap Fund Direct Growth Very High Risk	0.6%	1.0%	₹13830.67 Cr	6.4%
Mirae Asset Balanced Advantage Fund Direct Growth Moderately High risk	0.6%	1.0%	₹1695.72 Cr	10.4%

Risk Level

Your principal amount will be at Very High Risk

Take control of your wealth

Track and Analyse all your investments with Wealth Monitor

Rated ★ 4.3+ on

Still got questions?
We're here to help.

What is the current NAV of Mirae Asset Healthcare Fund Direct Growth?

The NAV of Mirae Asset Healthcare Fund Direct Growth, as of 27-Mar-2025, is ₹40.39.

What are the returns of Mirae Asset Healthcare Fund Direct Growth?

The fund has generated 19.94% over the last 1 year and 19.48% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.

What is the portfolio composition of Mirae Asset Healthcare Fund Direct Growth?

The fund's allocation of assets is distributed as 99.60% in equities, 0.00% in bonds, and 0.39% in cash and cash equivalents.

Who manages the Mirae Asset Healthcare Fund Direct Growth?

The fund managers responsible for Mirae Asset Healthcare Fund Direct Growth are:-

Vrijesh Kasera

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.

;

Fund Overview

Fund Size

₹2,441 Cr

Expense Ratio

0.52%

ISIN

INF769K01ED6

Minimum SIP

₹1,000

Exit Load

1.00%

Inception Date

02 Jun 2018

Risk Level

Your principal amount will be at Very High Risk